YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the National Cancer Centre of Singapore has selected nimotuzumab, YM’s EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck.
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.